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Background: Genetic methods for inducibly and reversibly inhibiting neuronal activity of specific neurons are
critical for exploring the functions of neuronal circuits. The engineered human glycine receptor, called ivermectin
(IVM)-gated silencing receptor (IVMR), has been shown to possess this ability in vitro.
Results: Here we generated a mouse line, in which the IVMR coding sequence was inserted into the ROSA26
locus downstream of a loxP-flanked STOP cassette. Specific Cre-mediated IVMR expression was revealed by
mis-expression of Cre in the striatum and by crossing with several Cre lines. Behavioral alteration was observed
in Rosa26-IVMR mice with unilateral striatal Cre expression after systemic administration of IVM, and it could be
re-initiated when IVM was applied again. A dramatic reduction in neuron firing was recorded in IVM-treated free
moving Rosa26-IVMR;Emx1-Cre mice, and neuronal excitability was reduced within minutes as shown by recording
in brain slice.
Conclusion: This Rosa26-IVMR mouse line provides a powerful tool for exploring selective circuit functions in freely
behaving mice.
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Understanding causal links between the activity of specific
neuronal circuits and behavior is critical and challenging.
Numerous efforts have been made to achieve this, and vari-
ous tools have been developed to perturb circuit function,
such as Molecular System for the Inactivation of Synaptic
Transmission, optogenetics (e.g. rhodopsin/halorhodopsin)
and ligand-gated ion channels [1-4].
Several ligand-gated channels have been developed to
inactivate defined neuronal population in an inducible
and reversible way. The Drosophila allatostatin receptor,
which suppresses action potential generation upon se-
lective activation by allatostatin [5], has been used suc-
cessfully to inactivate neuronal activity in mammalian* Correspondence: lxu@vip.163.com; dingyuqiang@gmail.com
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unless otherwise stated.brain [6-8]. However, because allatostatin cannot cross
the blood-brain barrier, it must be delivered locally by
an invasive method and is inconvenient when a large
number of animals are used in behavioral experiment.
Recently, an engineered GABAA receptor, which is in-
sensitive to zolpidem, has been used for inducibly silen-
cing specific neurons [9]. One limitation of this system
is that it cannot be used in neurons without expressing
GABAA γ2 subunit [1]. The third system of reducing
neuronal firing is the IVM-gated chloride channel from
C. elegans GluCl α and β subunits, and this works well
in mice as shown by amphetamine-induced rotational
behavior [10,11]. The potential limitation of this method
is the requirement of expressing the two different sub-
units in the same neuronal population, which may limit
its use. To overcome this, the human α1 glycine recep-
tor was modified by mutation of F207A and A288G,
named as IVMR, which is insensitive to glycine but sen-
sitive to IVM, and able to reduce neuronal excitabilityThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 2 AAV2-Cre-mediated IVMR expression in the striatum
of Rosa26-IVMR mice. Mice were sacrificed 14 d after injection of
AAV2-Cre virus. (a) IVMR expression shown by GFP immunostaining
and in situ hybridization is present in Rosa26-IVMR mice, but not in
Rosa26-IVMR mice without AAV2-Cre or in wild type mice with
AAV2-Cre injection. AAV2-Cre virus also expresses GFP. (b) Human
glycine receptor immunoreactivity (red) is located in NeuN-
immunopositive (green) neurons in the striatum of Rosa26-IVMR
mice. Arrows point to NeuN/IVMR-double positive neurons, and
Hoechest (blue) indicates nuclei. Scale bars, 200 μm in (a) and left
panel in (b), and 40 μm in the other panels in (b).
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and reversible silencing neurons.
In this study, the IVMR coding sequence was knocked
into Rosa26 locus downstream of a loxP-flanked STOP
cassette. Specific Cre-mediated IVMR expression was
verified by in situ hybridization and immunostaining,
and inducible and reversible inactivation of neuronal ac-
tivity was revealed by two behavioral observations. Reduc-
tion of neuronal firing was recorded in the hippocampus
of free moving Rosa26-IVMR;Emx1-Cre mice, and data
from brain slice suggested that this reduction is caused by
reduced neuronal excitability.
Results
Morphological characterization of Rosa26-IVMR mice
Rosa26-IVMR mice were generated by knocking IVMR-
2A-GFP coding sequence into the Rosa26 locus (Figure 1).
Homozygous and heterozygous Rosa26-IVMR mice were
viable, fertile, normal in size, and did not display any gross
physical abnormalities. Cre-mediated IVMR expression
was revealed by in situ hybridization for IVMR mRNA. As
shown in Figure 2a, injection of AAV2-Cre virus into the
striatum resulted in local IVMR expression in Rosa26-
IVMR mice but not wild type mice although Cre was
misexpressed (Additional file 1: Figure S1). Immnostain-
ing of the human glycine receptor showed intense im-
munoreactivity within the neurons of the virus-injected
area (Figure 2b). In addition, Rosa26-IVMR mice were
crossed with several Cre lines to further confirm Cre-
mediated IVMR expression. In Rosa26-IVMR;CamKII-Cre
mice, IVMR mRNA was abundantly distributed in the
cerebral cortex, hippocampus and thalamus (Figure 3b,c),Figure 1 Gene targeting of the IVMR-2A-GFP sequence into the ROSA
targeting construct and the expected recombination events. CAG, CAG pro
regulatory element; pA, polyA sequence; PGK, PGK promoter; NeoR, neomy
negative selection cassette. (b) 5′arm and 3′arm PCR analysis showing the
(c) Genotyping of mouse pups to identify offspring harboring the conditiowhich is consistent with the Cre expression pattern in
CamKII-Cre mice [13]. With the help of 2A-peptide self-
processing system (Figure 1), which ensures faithful ex-
pression of multiple proteins [14], GFP could be used to
detect IVMR expression. The expression pattern of GFP26 locus by homologous recombination. (a) Diagram of the
moter; WPRE, the woodchuck hepatitis virus posttranscriptional
cin resistance positive selection cassette; DTA, diphtheria toxin
identification of positive targeted ES clones (Lanes 2, 4, 5, 7 and 10).
nal allele.
Figure 3 IVMR expression in Rosa26-IVMR mice crossed with 3
Cre lines. (a-d) GFP immunostaining and IVMR in situ hybridization
in the hippocampus (a, c) and cerebral cortex (b, d) of Rosa26-IVMR;
CamKII-Cre mice. (e, f) Expression of IVMR mRNA in the hippocampus
(e) and cerebral cortex (f) of Rosa26-IVMR;Emx1-Cre mice. (g, h)
Expression of IVMR mRNA in the spinal dorsal horn (g) and dorsal
root ganglion (h) of tamoxifen-treated Rosa26-IVMR;Prrxl1-CreER
mice. CA1, CA1 region of the hippocampus; df, dorsal fasciculus;
DG, dentate gyrus; DH, dorsal horn; lf, lateral fasciculus; I-VI, cortical
layers. Scale bars, 200 μm in (f) applies to (a-e), 150 μm in (g) and
100 μm in (h).
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although it was localized also in dendrites in addition to
cell bodies (Figure 3a,b). In addition, Cre-dependent
IVMR expression was observed in Rosa26-IVMR;Emx1-
Cre mice, which was abundantly distributed in the cere-
bral cortex and hippocampus (Figure 3e,f), consistent with
Cre expression pattern of Emx1-Cre mice [15]. However,
no IVMR mRNA or GFP immunoreactivity was detected
in Rosa26-IVMR mice without Cre (Figure 1a). Taken to-
gether, we have shown that Cre-dependent IVMR expres-
sion can be achieved in Rosa26-IVMR mice allowing
IVMR expression in specific cell-type neurons.
Functional characterization of Rosa26-IVMR mice
Unilateral disruption of the nigrostriatal pathway is widely
used in studying movement disorders, and animals with
unilateral damage to the striatum show rotation towardsthe lesioned side in the presence of amphetamine or
apomorphine [11,16]. Apomorphine-induced rotation
therefore can be used at a behavioral level to explore
the efficacy of genetic tool in silencing neuronal activity.
The mice were placed into 40 × 40 cm open field box
(Med Associate, USA), their locomotion was videotaped,
and rotation behaviors were analyzed 5 min after adminis-
tration of apomorphine using Ethovision XT8 software
(Noldus Inc., The Netherland). Full 360° rotations without
any changes in direction were counted for 20 min. Rota-
tion scores were calculated by subtracting contralateral
from ipsilateral rotations and dividing by the total travel
distance.
In Rosa26-IVMR mice with unilateral injection of the
AAV2-Cre virus, administration of apomorphine re-
sulted in an obvious rotation towards the injection side
12 h after a single intraperitoneal administration of IVM
at 10 mg/kg (Figure 4a). No rotation behaviors were
found in AAV2-Cre virus-injected Rosa26-IVMR mice
without IVM or apomorphine treatment, or in Rosa26-
IVMR mice without AAV2-Cre virus injection, or in wild
type control (Figure 4a). Thus, systemic administration
of IVM is able to activate IVMR of striatal neurons lead-
ing to behavioral alteration.
We then examined rotation behaviors at later time
points. As shown in Figure 4b, apomorphine-induced ro-
tation reached peak level at 1 d and 2 d, reduced at 3 d
and disappeared at 5 d and 7 d. We next explored dose
responses of IVM. IVM at 5 mg/kg also led to obvious
rotation behaviors, but the time window was narrowed
to a 12 h-1d period (Figure 4b). When IVM was applied
at 2.5 mg/kg, no obvious rotation behaviors were found
relative to those at 5 and 10 mg/kg (Figure 4c). Because
5 mg/kg of IVM induced similar rotation behaviors at
12 h relative to 10 mg/kg, we used this concentration to
examine the earliest onset of apomorphine-induced rota-
tion. Clear rotation behavior was detected at 9 h after
systemic administration of IVM, but rotation scales var-
ied greatly among animals (Additional file 2: Figure S2);
this may reflect insufficient neuron silencing because
IVM has not reach required concentration for activation
of IVMR. Nevertheless, IVM is able to inhibit the activ-
ity of striatal neurons of Rosa26-IVMR mice in a revers-
ible way and this effect is IVM dose-dependent.
We next set out to explore if the striatal neurons can
be re-inactivated with IVM in the same mice. Mice were
treated with IVM (10 mg/kg) again 3 weeks after the ini-
tial IVM administration (10 mg/kg). Apomorphine-
induced rotation was examined at 1 d, and rotation
score was not different from that obtained in the initial
IVM administration (Figure 4d). These results indicate
that IVMR maintains its sensitivity to IVM in mouse
brain offering the availability of multiple cycles of
neuron silencing.
Figure 4 IVM-induced behavioral alteration in free moving Rosa26-IVMR mice. (a) Rotation towards AAV2-Cre virus-injected side is only
present in Rosa26-IVMR mice treated with both apomorphine and IVM but not those treated with one of them. Wild type controls do not show
any rotation when treated with both of them or either of them. Apomorphine-induced rotation was performed 12 h after administration of IVM
(10 mg/kg). n = 6 for wild type; n = 8 for Rosa26-IVMR mice; ***P < 0.001, two-way repeated ANOVA test. (b) Time course of apomorphine-induced
rotation in Rosa26-IVMR mice with unilateral injection of AAV2-Cre virus. n = 9 for each; **P < 0.01 (5 mg/kg vs 10 mg/kg group), two-way repeated
ANOVA test. (c) Dose effect of IVM on apomorphine-induced rotation in Rosa26-IVMR mice at 12 h and 1 d post systemic administration. Six to eleven
mice were included in each set of experiments; **P < 0.01, one-way ANOVA test. (d) Apomorphine-induced rotation is similar between the first- and
second cycles of IVM administration. This observation was done 1 d after IVM treatment (10 mg/kg). n = 6 for each; P = 0.7, paired samples test. (e)
Thermal sensation shown by the tail immersion test is lowered in Rosa26-IVMR;Prrxl1-CreER mice 1 d after administration of IVM (10 mg/kg), but
unchanged in wild type mice. n = 11 for wild type, n = 13 for Rosa26-IVMR;Prrxl1-CreER mice; *P < 0.05, two-way repeated ANOVA test. (f) Mechanical
sensation shown by the von Frey test is decreased in Rosa26-IVMR;Prrxl1-CreER mice at 1 d and 2 d after systemic administration of IVM, but unchanged
in wild type mice. n = 11 for wild type, n = 13 for Rosa26-IVMR;Prrxl1-CreER mice; *P < 0.05, **P < 0.01, two-way repeated ANOVA test.
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ined also in Rosa26-IVMR;Prrxl1-CreER mice [17], in
which Cre-mediated IVMR expression was induced by
tamoxifen treatment in the sensory neurons located in the
dorsal root ganglia and spinal dorsal horn (Figure 3g, h).
Transcription factor Prrxl1 is selectively expressed in the
somatosensory system and involved in the somatosensory
sensation [18-20]. The tail immersion test was used to
examine thermal sensation 1 d after systemic administra-
tion of IVM. Tail flick latency was largely increased in
IVM-treated Rosa26-IVMR;Prrxl1-CreER mice at 50°C and52°C, as compared with that obtained before IVM treat-
ment and those from wild type controls before and post
IVM treatment (Figure 4e). Wild type mice treated with
IVM did not show a difference in the latency relative to
that before IVM treatment (Figure 4e). In addition, the
threshold for mechanical sensation shown by the von Frey
test was increased also in IVM-treated Rosa26-IVMR;
Prrxl1-CreER mice (Figure 4f). To know the persistence of
IVM-induced silencing effect, the von Frey test was per-
formed at later time points. A significant increase in paw
withdrawal threshold was observed also at 2 d, but it
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sults indicate that somatosensation is reduced in IVM-
treated Rosa26-IVMR;Prrxl1-CreER mice and IVMR is
functional in Rosa26-IVMR mice crossed with transgenic
Cre mice.
Because a higher dose of IVM (e.g. 20 mg/kg, i.p.) in-
duces tremors and partial paralysis in some mice [11,21],
we examined the locomotor activity by open field test in
wild type mice and Rosa26-IVMR mice treated with
10 mg/kg of IVM, the maximal concentration used in
this study. There were no differences in distance traveled
and speed recorded before and after IVM treatment in
these mice (Figure 5a). Meanwhile, the time spent in the
center area of the open field was similar before and after
IVM treatment, reflecting no changes in the anxiety-like
behaviors. This was further supported by the light/dark
choice tests, in which the numbers of entering into and
times spent in the light box also showed no differences
before and after IVM treatment in the mice (Figure 5b).
In addition, the contextual fear memory was similar be-
tween vehicle- and IVMR-treated wild type mice during
both the training and retrieval periods (Figure 5c). We
conclude that systemic IVM administration does not
obviously affect locomotor activity, anxiety or context-
ual fear memory.Figure 5 Locomotor activity, anxiety-like behaviors and contextual fe
(a) The open field test shows that the total distance traveled, speed, and ti
and after IVM treatment. (b) The number of entering into and time spent i
after IVM treatment in the light/dark choice test. (c) Freezing time in the tr
IVM-treated mice in the contextual fear memory test.To examine if activation of IVMR inhibits neuronal
firing, we performed in vivo recoding in free moving
Rosa26-IVMR;Emx1-Cre mice by placing multiple elec-
trodes in the hippocampus, which contained numerous
neurons expressing IVMR (Figure 3f ). After an intraperi-
toneal injection of IVM (10 mg/kg), a significant reduc-
tion of neuron firing rate was first observed at 8 h, and
this reduction reached the lowest level at 12 h and main-
tained at 1 d (Figure 6a). However, IVM administration
did not alter neuron firing in wild type mice (Figure 6a).
Thus, a single IVM treatment leads to a long-lasting re-
duction of hippocampal neuron firing in Rosa26-IVMR;
Emx1-Cre mice.
It takes time for IVM to reach the brain and to reduce
neuronal firing via activation of IVMR after systemic ad-
ministration of IVM. To know how fast IVM activates
IVMR and reduces neuronal firing, we made electro-
physiological recording from brain slices prepared from
Rosa26-IVMR;Emx1-Cre mice. We found that the excit-
ability of hippocampal neurons, shown by the minimal
current injection (current threshold) evoking neuronal
firing, was dramatically reduced in Rosa26-IVMR;Emx1-
Cre mice, whereas it was unchanged in wild type con-
trols after IVM treatment (Figure 6b). In addition, action
potential frequency evoked by intracellular currentar memory are not altered by IVM treatment in wild type mice.
me spent in the center area are not different in the mice before
n the light box are not significantly different in mice before- and
aining and retrieval periods is not different between the vehicle- and
Figure 6 IVM-induced reduction of neuron firing and excitability in Rosa26-IVMR mice. (a) Neuron firing in the hippocampus of
Rosa26-IVMR;Emx1-Cre mice is reduced after systemic administration of IVM. A significant reduction of neuron firing is present at 8 h, and it
reaches the lowest level at 12 h and persists at 1 d. Recording was performed in free moving mice; 19 neurons from 4 wild type mice and 18
neurons from 2 Rosa26-IVMR;Emx1-Cre mice were included. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA. Recordings from two reparative
neurons in channel 3 and 7 are shown in the right panel. (b) Cortical neuron excitability shown by ratio of current threshold before and after IVM
treatment is reduced in Rosa26-IVMR;Emx1-Cre mice after bath application of IVM, whereas it was unchanged in wild type mice. n = 7 for wild
type, n = 8 for Rosa26-IVMR;Prrxl1-CreER mice; *P < 0.05; 2-tailed Student’s t-test. (c) Time course of action potential frequency initiated by injection
of current (450 pA, 400 ms) after bath application of IVM (10 nM, 3 min). Action potential frequency was normalized to that obtained before IVM
treatment for comparison. Note that the frequency of action potential decreased rapidly and dramatically after IVM treatment. n = 6 for wild type,
n = 5 for Rosa26-IVMR;Prrxl1-CreER mice. *P < 0.05, **P < 0.01, ***P < 0.001; two-way repeated ANOVA test.
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within minutes after bath application of IVM in Rosa26-
IVMR;Emx1-Cre mice. By contrast, action potential fre-
quency remained unchanged in wild type controls after
IVM treatment (Figure 6c). These results demonstrate
that IVM is able to lead to a reduction of neuronal firing
by lowering its excitability in Rosa26-IVMR;Emx1-Cre
mice.
Discussion
Here we generated Rosa26-IVMR mice in which IVM
reduced neuronal activity in a cell type-specific manner.
IVMR expression was present in Rosa26-IVMR mice in
the presence of virus-delivered Cre and when crossed
with Cre lines, and reversible inhibition of neuronal ac-
tivity was induced by systemic administration of IVM.
This mouse line offers a new genetic tool for exploring
the causal relationship between the silencing of specific
neuronal circuits and behaviors.
Specific Cre-mediated IVMR expression in Rosa26-
IVMR mice was confirmed by injecting of AAV2-Cre virus
and crossing with several Cre lines (Figures 2 and 3).
The ability of IVMR activation to silence neuronal activ-
ity was revealed by recording neuronal firing in freemoving animals, and in brain slices (Figure 6) and by
observing behavioral alteration (Figure 4). The data
from apomorphine-induced rotation indicates that an
obvious and steady behavioral alteration is observed at
12 h post systemic administration of IVM (Figure 4).
This delay may reflect the timing for IVM to reach suffi-
cient concentration in the brain for activating IVMR
and inhibiting neuronal activity, because it takes only a
few minutes for IVM to reduce neuronal excitability in
brain slices (Figure 6). It is possible that intraventricular
administration of IVM would achieve a faster onset of
neuronal silencing if desired. Peak behavioral alteration
was observed at 1 d, and decreased at 3 d but no longer
existed at 5 d. This long-lasting silencing effect in vivo
could be beneficial in experiments where continuous si-
lencing is required during extended behavioral perfor-
mances. However, this could be a disadvantage in some
experiments requiring fast recovery. This long-lasting
effect is consistent with the published data concerning
the property of IVM-gated GluClαβ, and it may be
caused by slow ligand clearance/metabolism and dis-
sociation of IVM from the channels [11].
We examined the dose-dependent effect of IVM in
apomorphine-induced rotation. IVM at 5 and 10 mg/kg
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of IVM resulted in a longer period of rotational behavior
compared with 5 mg/kg (1.5 d vs 12 h; Figure 4). Mech-
anical sensation shown by the von Frey test also indi-
cated that 10 mg/kg of IVM led to a marked increase in
the paw withdrawal threshold by 2 d after IVM adminis-
tration. Together with other behavioral data, we have
shown that both 5 and 10 mg/kg IVM is sufficient to in-
hibit neuronal activity in vivo, and that 5 mg/kg can be
used if a shorter period of silencing is desired.
The inducible, reversible and re-activatable properties
of the IVMR offer a unique advantage for designing ex-
periments. The possible relationship between neuron
circuit activity and behaviors can be verified repeatedly
in the same mice, pre-IVM, post-IVM (phenotype), re-
covery and post-IVM (restore phenotype). Meanwhile,
other methods of manipulating neuron activity [1-4] can
be applied in the second cycle of neuronal silencing to
clearly dissect the causal link between the specific neur-
onal circuit and behavior.
IVM is a toxic drug used for treatment of animals with
infection of arthropod and parasitic nematode. The con-
centrations required for silencing neuron is between 5-
10 mg/kg, which is higher than that used in anti-parasitic
treatment. Chronic administration of IVM in the drinking
water does not affect general health, body weight, motor
coordination, swimming behavior, or spatial learning in
mice [22]. Intraperitoneal injection of 20 mg/kg IVM and
above induced tremors and partial paralysis in some mice,
but this and a previous study [11] did not observe this ad-
verse effect on locomotion when 5-10 mg/kg IVM was
injected intraperitoneally. Additionally, IVM reduced alco-
hol intake and preference in mice [23], and 20 mM IVM
could lead to maximal activation of GABA receptors
expressed in HEK 293 cells [24]. Although we did not ob-
serve an obvious alteration in anxiety-like behaviors and
contextual fear memory (Figure 5), it would be advisable
to examine the adverse effects of IVM when Rosa26-
IVMR mice were crossed with other mouse lines with ab-
normal GABA system or in cases of combination use of
other chemicals/drugs that may affect clearance/metabol-
ism of IVM.
Materials and methods
Generation of Rosa26-IVMR mice
Targeting constructs were generated using molecular clon-
ing approach. Briefly, to target the Rosa26 locus, a cassette
containing the IVMR-2A-GFP gene was constructed
[12,14]. This cassette was cloned into a Rosa-CAG tar-
geting vector [25], in which dtTomato was replaced with
IVMR-2A-GFP gene to generate the final IVMR knock-in
vector (Figure 1a). The final targeting vectors contained 5′
and 3′ homology arms of 1.1 kb and 4.3 kb, as well as
a PGK-DTA cassette for negative selection. The targetingvectors were linearized and transfected into the 129/B6 F1
hybrid ES cell line G442 using an Amaxa electroporator.
G418-resistant ES clones were screened by PCR and se-
quencing combined analysis. PCR primers were designed
according to the expected insertion pattern. The 5′ arm
forward primer was designed according to the wild type
sequences of the up-stream of the insertion site (5′-CGC
GGAACTCCATATATGGGCTATG-3′), and the reverse
primer was designed according to the insertion sequences
down-stream of the insertion site (5′-GGCTCCTCAGAG
AGCCTCGGCTAG-3′). Similarly, the 3′ arm forward
primer was designed according to the inserted NeoR gene
(5′-AGACCATTCTCAGTGGCTCAACAAC-3′) and the
reverse primer was designed according to the wild type
sequences of the down-stream of the insertion site (5′-
ATTCGGCTATGACTGGGCACAACA-3′). Positive ES
clones were injected into C57BL/6 J blastocysts to ob-
tain chimeric mice that were bred with C57BL/6 J mice
to obtain germline transmission.
Animals
Adult (2-4 month old) Rosa26-IVMR mice were used. All
animal care and experimental protocols were reviewed
and approved by the Animal Research Committee of
Tongji University School of Medicine, China.
Cre-mediated IVMR expression was examined in
Rosa26-IVMR mice. The AAV2-Cre virus was prepared
as reported previously [26,27], and was injected unilat-
erally into the striatum, Mice were sacrificed for detec-
tion of IVMR expression 14 d later, and this was used to
show if IVMR expression could be induced by local de-
livery of Cre-expressing virus. Second, Rosa26-IVMR
mice were crossed with Emx1-Cre [15], CamKII-Cre
[13] and Prrxl1-CreER [17] mice to show if IVMR ex-
pression could be activated by crossing with Cre line
mice.
Behavioral observation
Two behavioral paradigms were used to evaluate the ef-
fects of IVM-induced neuron silencing in Rosa26-IVMR
mice. Two weeks after unilateral injection of AAV2-Cre
virus into the striatum, IVM at doses of 2.5, 5.0 and
10.0 mg/kg (Jiangsu East China Bell Co., China) was ad-
ministered by a single intraperitoneal injection, and
apomorphine-induced rotation behaviors were examined
at different time points. At each time point, apomorph-
ine (5 mg/kg, i.p.; Sigma, USA)-treated mice were
placed in Activity Monitor (Med Associates) for 20 min
and rotation index was calculated by using EhtoVision
XT8 software (Noldus, The Netherlands) as reported
previously [11]. Rotation scores were calculated by
subtracting contralateral from ipsilateral rotations
and dividing by the total distance travelled (m), namely
rotation scores = rotation numbers/distance (m). To
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behavioral observation was performed again in the same
mice 3 weeks after the initial IVM administration. Six
cohorts of mice were used in this set of experiment to
ensure at least a 1-day interval between two apomorph-
ine treatments.
The second behavioral observation was performed in
Rosa26-IVMR;Prrxl1-CreER mice. Cre recombinase was
induced by tamoxifen treatment as reported in our pre-
vious study [17]. Four weeks later somatosensory sensa-
tion was examined by both the von Frey test [28] and
the tail immersion test (50°C and 52°C) at 1 d post a sin-
gle administration of IVM (10 mg/kg; i.p.). In addition,
to explore if IVM affects locomotor activity, wild type
mice and Rosa26-IVMR mice with unilateral injection of
AAV2-Cre virus were placed in a plexiglass box (Med
Associates) and locomotor activity was monitored over a
30-min period. Four to seven days later, the same mice
were treated with IVM (10 mg/kg, i.p.), and locomotor
activity was monitored again at 1d post IVM treatment.
Furthermore, the light/dark choice test was used to
examine if the anxiety-like behaviors were altered by
IVM. These examinations were performed in the wild
type mice. Mice were subjected to the test without IVM
first, and 7-10 d later to the test again with IVM injec-
tion that was done 1d before the test commenced. The
light/dark choice test apparatus consisted of a small
dark chamber (30 cm × 20 cm × 30 cm) connected by an
opening (5 cm × 7 cm) to a larger lit chamber (30 cm ×
30 cm × 30 cm). A single mouse was initially placed in
one corner of the dark chamber and the percentage of
time spent in the lit chamber was measured over 5 min.
Contextual fear conditioning was performed as
described in our previous study [29]. FreezeFrame and
FreezeView software systems (Coulbourn Instruments,
USA) were used to record and analyze freezing behaviors.
Wild type mice treated with vehicle or IVM (10 mg/kg,
i.p.) were given five foot shocks (0.7 mA, 2 s) at 2 min in-
tervals during which the mice were able to move freely.
The percentage of freezing time was measured during
each inter-shock interval. Thirty minutes, 1 d, 2 d and 13
d later, the mice were placed back in the same box for
11 min without receiving any foot shocks, and freezing
time was measured to test contextual fear memory.Immunohistochemistry and in situ hybridization
Mice were anesthetized deeply with sodium pentobar-
bital and perfused through the ascending aorta with
0.01 M phosphate buffered saline (PBS; pH 7.4) followed
by 4% paraformaldehyde in 0.1 M phosphate buffer
(pH 7.4). After cryoprotection with 30% sucrose in PBS,
samples were cut transversely into 40 μm-thick sections
on a cryostat. The following primary antibodies wereused: mouse anti-NeuN antibody (1:1000; Chemicon,
USA), rabbit anti-human glycine receptor antibody (1:200;
Millipore, USA) and rabbit anti-GFP antibody (1:1000;
Invitrogen, USA). Sections were incubated with the
anti-GFP antibody overnight at 4°C, and then with bio-
tinylated goat anti-rabbit secondary antibody (1:500;
Vector Laboratories, USA) for 2 h at room temperature,
followed by incubation with the avidin-biotin complex
(Vector Laboratories). Immunoreactive signals were de-
tected by using 3,3′-diaminobenzidinetetrahydro-chloride
(Sigma, USA) as a chromogen. For double immunofluor-
escence, sections were incubated with a mixture of rabbit
anti-human glycine receptor and mouse anti-NeuN
antibodies, followed by a mixture of Alexa Fluor 488-
conjugated anti-mouse (1:500; Invitrogen, USA) and
Cy3-labeled anti-rabbit IgG (1:500; Jackson ImmunoRe-
search, USA). Sections were observed under a Nikon
fluorescence microscope equipped with a Nikon Cool-
pix digital camera (DS-Ri1; Japan) or using laser con-
focal microscope (TCS SP5 II; Leica, Germany).
Antisense digoxigenin-labeled RNA probes for the
human Glycine receptor were synthesized and in situ
hybridization was performed as described previously
[18]. All images were made into figures using Adobe
Photoshop (Adobe Systems Incorporated, USA) and only
minor adjustments to the contrast and brightness settings
were applied if necessary.In vivo electrophysiological recording
For extracellular recording of neuron firing, adult free
moving Rosa26-IVMR;Emx1-Cre mice were used. The
recording electrode bundle contains 32 single wires
(California FineWire, USA). Under anesthesia with so-
dium pentobarbital (8 mg/kg, i.p.), and the tips of the
electrodes were positioned to encounter dorsal CA1 re-
gion, according to the specific local field potential and
neuronal activity patterns. After stabilization with den-
tal cement, mice were allowed to recover for 7 d. Princi-
pal component analysis was used to extract defining
features from the spike wave shapes, and units were iso-
lated using spike sorting software (Offline Sorter 3.0,
USA). Stable units must be well isolated before experi-
ments. During experiments, we recorded the activity of
individual neurons during freely moving states. Each
mouse underwent numerous recording sessions through
the whole experiment. Firing frequency of individual
neuron after IVM treatment was normalized to that be-
fore IVM treatment for comparison.In vitro electrophysiological recording
For recording in brain slice, 3-6 weeks old Rosa26-
IVMR;Emx1-Cre mice were used. Transverse brain slices
(350 μm) were cut on a vibrating microslicer (Leica
Hu et al. Molecular Brain 2014, 7:68 Page 9 of 10
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were performed after the brain slices were incubated for
1 h in external artificial CSF (in mM: NaCl 117, KCl 3.6,
CaCl2 2.5, MgCl2 1.2, NaH2PO4 1.2, NaHCO3 25 and
glucose 11) which was bubbled continuously with carbo-
gen (95%O2/5%CO2). Recording pipettes with resistances
of 3–5 MΩ were pulled from borosilicate glass (P-97;
Sutter Instruments, USA) and filled with a solution of
(in mM) potassium gluconate 135, KCl 5, CaCl2 0.5,
MgCl2 2, EGTA 5, HEPES 5 and ATP-Mg 5. Evoked ac-
tion potential were measured in layer II-III cortical neu-
rons in current clamp mode. The signals were amplified
with an Axopatch 700B amplifier (Molecular Devices,
USA), filtered at 2 kHz, and digitized at 5 kHz. The data
were stored and analysed with a personal computer using
software of pCLAMP 10. The minimal injected current
for evoking action potential (current threshold) were
measured first, and was measured again after bath
application of IVM (10 nM; Sigma). Current threshold
obtained after IVM treatment was normalized to that
before IVM treatment for statistical comparison. In
addition, time course of action potential frequency initi-
ated by injection of current (450 pA, 400 ms) was ex-
amined as well.Quantification and statistics
Data are expressed as mean ± SEM. Differences between
two groups were compared using 2-tailed Student’s t-
test. One way ANOVA followed by a Fisher post hoc test
to evaluate the differences of rotational scores among
multiple concentration groups in 12 h and 24 h, respect-
ively. Two way repeated ANOVA was used for compari-
son of rotational score between 10 mg/kg and 5 mg/kg
IVM groups in various time points and two different
genotypes between before and after IVM treatment. All
the data were analyzed using PASW Statistics 18. The
criterion for statistical significance was P < 0.05.Additional files
Additional file 1: Figure S1. Double immunostaining showing Cre
expression in the striatum of wild type mice injected with AAV2-Cre virus.
AAV2-Cre virus contains GFP expressing sequence. Arrows indicate neurons
expressing both GFP and Cre immunoreactivity. Scale bars = 150 μm (a-a”)
and 50 μm (b-b”).
Additional file 2: Figure S2. Time course of apomorphine-induced
rotations in Rosa26-IVMR mice treated with 5 mg/kg IVM. Obvious
rotation behaviors are present at 5 h and 9 h post IVM treatment, while
rotation scores at these two time points varied greatly relative to those at
later time points. n = 9.Abbreviations
CA1: CA1 region of hippocampus; DG: Dentate gyrus; DH: Spinal dorsal horn;
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